AKTS

At a glance

Aktis Oncology, Inc. (AKTS) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Boston, United States and has 79 employees. The company is worth $837.63M. Revenue was $6.5M in fiscal 2025, up 336.9% from the year before. It reported a net loss of $63.73M. The share price is 56.0% below its 52-week high of $34.19. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to George Soros (Soros Fund Management), at $3.22M. In that quarter, 2 of them opened or added to the position and 1 reduced it. Over the last 30 days, company insiders sold $258.62K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$837.63M

P/E

—

Forward P/E

—

P/B

1.7x

Dividend yield

0.00%

Payout

—

EPS

-$1.70

ROE

—

Profit margin

0.00%

Revenue growth

+111.40%

Beta

—

52-week high

$34.19

52-week low

$14.72

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• 
  George SorosHeld

  Soros Fund Management · Q2 2026
  $3.22M

  100K shares · 0.1% of portfolio
• RT
  Renaissance Technologies+ New position

  Renaissance Technologies · Q2 2026
  $3.07M

  95.4K shares · 0.0% of portfolio
• CA
  Cliff Asness+ New position

  AQR Capital Management · Q2 2026
  $1.55M

  48.12K shares · 0.0% of portfolio

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company